Interventional Radiology Imaging

Why Is Anticoagulation the Initial Therapy for Low-Risk Bilateral Pulmonary Embolism?

·
Why Is Anticoagulation the Initial Therapy for Low-Risk Bilateral Pulmonary Embolism?

A 58-year-old woman presents to the emergency department with acute-onset shortness of breath and pleuritic chest pain one week after a total knee arthroplasty. A computed tomography angiography (CTA) of the chest confirms bilateral segmental and subsegmental pulmonary emboli. The radiology report notes an RV/LV ratio of 0.85. Her blood pressure is stable, troponin levels are normal, and a point-of-care echocardiogram shows no evidence of right heart strain. The clinical question is immediate: what is the appropriate initial therapy for this patient? This article provides a detailed workflow for this specific scenario, where the American College of Radiology (ACR) rates anticoagulation as ‘Usually appropriate’ as the definitive initial management.

Who Fits This Clinical Scenario for Low-Risk Pulmonary Embolism?

This guidance applies to a specific subset of adult patients with a confirmed diagnosis of acute pulmonary embolism (PE). The key is that while the PE is bilateral, all markers point toward a low-risk, hemodynamically stable presentation.

Inclusion criteria for this workflow:

  • Diagnosis: Acute bilateral pulmonary emboli confirmed on imaging.
  • Hemodynamics: The patient is normotensive, with no signs of shock or sustained hypotension.
  • CTA Findings: The right ventricular to left ventricular (RV/LV) diameter ratio is less than 0.9. This measurement is a critical indicator that the right ventricle is not acutely dilated or failing due to the pressure load from the PE.
  • Biomarkers: Serum troponin levels are within the normal range, indicating no myocardial injury or strain.
  • Echocardiography: If performed, there is no evidence of right heart strain (e.g., normal RV size and function, no paradoxical septal motion).

Exclusion criteria (patients who require a different workflow):

  • Submassive PE: Patients with an RV/LV ratio greater than 0.9, elevated troponins, or echocardiographic evidence of right heart strain fall into the submassive PE category. Their management is more complex and may involve more aggressive therapies.
  • Massive PE: Patients presenting with sustained hypotension, syncope, or signs of cardiogenic shock are classified as having massive PE. This is a medical emergency requiring immediate escalation, often to therapies like systemic thrombolysis or embolectomy.
  • Contraindications to Anticoagulation: Patients with active, significant bleeding or a very high risk of bleeding may not be candidates for this pathway and require alternative considerations, such as IVC filter placement.

What Is the Primary Therapeutic Goal in This Scenario?

For a patient with a confirmed low-risk pulmonary embolism, the diagnostic journey is largely complete. The focus immediately shifts from diagnosis to risk-stratified therapy. The primary therapeutic goal is to prevent the extension of the existing thrombus and to stop the formation of new, recurrent emboli, all while minimizing the risk of treatment-related complications.

In this specific scenario, the patient’s own fibrinolytic system is generally capable of gradually breaking down the existing clot over time, provided it is not overwhelmed. The key is to halt the underlying thrombotic process with effective anticoagulation. This allows for physiological clot resolution and prevents the patient from deteriorating into a higher-risk category.

The “workup” at this stage is less about a differential diagnosis for the symptoms (which are explained by the PE) and more about confirming the patient’s low-risk status. The normal RV/LV ratio, stable vital signs, and negative biomarkers collectively indicate that the patient’s cardiopulmonary reserve is sufficient to handle the current clot burden. Therefore, the therapeutic strategy is aimed at stabilization and prevention, rather than emergent clot removal. The clinical question is not if the patient needs treatment, but rather which treatment offers the best balance of efficacy and safety for this low-risk profile.

Why Is Anticoagulation the Recommended Initial Therapy for Low-Risk PE?

For an adult with acute bilateral pulmonary emboli who is hemodynamically stable and shows no signs of right heart strain, the American College of Radiology designates Anticoagulation as ‘Usually appropriate’. This recommendation is based on a careful weighing of therapeutic benefit against procedural and medication-related risk. In this low-risk cohort, anticoagulation effectively achieves the primary therapeutic goals without exposing the patient to the significant dangers of more invasive interventions.

The rationale for avoiding more aggressive therapies is clear:

  • Systemic Thrombolysis: This therapy is rated ‘Usually not appropriate’ for this scenario. While effective at rapidly dissolving clot, systemic thrombolytics carry a substantial risk of major bleeding, including a 1-2% risk of life-threatening intracranial hemorrhage. In a stable patient without right heart strain, this risk profile is unacceptable and far outweighs the potential benefit. The goal is to prevent deterioration, which anticoagulation achieves with a much higher safety margin.
  • Catheter-Directed Therapy (CDT): Also rated ‘Usually not appropriate’, CDT involves placing catheters directly into the pulmonary arteries to deliver thrombolytics or mechanically remove the clot. As an invasive procedure, it carries risks of vascular injury, access site complications, and bleeding. CDT is reserved for higher-risk (submassive) PE, where the evidence of impending hemodynamic collapse (i.e., right heart strain) justifies the procedural risk to achieve rapid clot reduction.
  • Surgical Embolectomy: This is a major open-heart surgical procedure rated ‘Usually not appropriate’ for low-risk PE. It is a high-risk intervention reserved for patients with massive PE who are in shock, have failed other therapies, or have an absolute contraindication to both thrombolysis and anticoagulation.

In summary, for the low-risk PE patient, anticoagulation is the cornerstone of therapy. It is highly effective at preventing clot propagation and recurrent VTE, allowing the body to recover while avoiding the severe complications associated with thrombolysis and invasive procedures.

What Is the Downstream Workflow After Starting Anticoagulation?

Once the decision is made to initiate anticoagulation, the clinical workflow transitions to monitoring, determining the duration of therapy, and planning for outpatient management. The “result” in this context is the patient’s clinical response.

  • If the patient remains clinically stable: This is the expected outcome. The patient should be monitored for signs of clinical improvement (resolving tachycardia, improving oxygenation) and for any signs of bleeding. The choice of anticoagulant (e.g., DOAC, LMWH, warfarin) will depend on patient-specific factors like renal function, comorbidities, and cost. The next major decision is whether the patient can be safely discharged from the hospital for outpatient management or requires a brief admission for observation.
  • If the patient clinically deteriorates: This is a red flag and a critical change in the patient’s risk category. Deterioration may manifest as new or worsening hypotension, increasing oxygen requirements, or new signs of right heart strain. This patient no longer fits the low-risk scenario. The workflow must escalate immediately to that of a submassive or massive PE, which involves reconsidering the advanced therapies (systemic thrombolysis, CDT) that were initially deemed inappropriate. This requires urgent consultation with a Pulmonary Embolism Response Team (PERT), critical care, and/or interventional radiology.
  • If bleeding complications occur: Management depends on the severity. Minor bleeding may be managed with observation. Major bleeding requires stopping the anticoagulant and may necessitate reversal agents. This situation also requires an urgent re-evaluation of the risk/benefit ratio of continuing therapy and may prompt consideration of an IVC filter.

The long-term plan involves determining the appropriate duration of anticoagulation (typically at least 3-6 months) based on whether the PE was provoked (e.g., by recent surgery) or unprovoked.

Pitfalls to Avoid (and When to Get Help)

Even in a seemingly straightforward low-risk PE scenario, several pitfalls can lead to poor outcomes.

  • Misclassifying the Patient: The most critical error is failing to recognize subtle signs of right heart strain. An RV/LV ratio of 0.89 is very different from 0.91. Be meticulous in reviewing all available data (CTA, echo, biomarkers) to ensure the patient is truly low-risk.
  • Delaying Anticoagulation: Once the diagnosis of PE is made in a patient without contraindications, anticoagulation should be started without delay. Delays can allow for thrombus propagation and clinical deterioration.
  • Ignoring Contraindications: Before starting anticoagulation, perform a thorough bleeding risk assessment. Overlooking a history of recent major bleeding, severe thrombocytopenia, or an intracranial mass can be catastrophic.
  • Failing to Monitor: A patient who is low-risk on presentation can become high-risk. Failure to closely monitor vital signs, oxygenation, and overall clinical status in the initial hours after diagnosis is a common pitfall.

If a patient develops any signs of hemodynamic instability, worsening respiratory status, or new evidence of end-organ dysfunction, this is a clear signal to escalate care. This should trigger an immediate consultation with a multidisciplinary team, such as a PERT, to rapidly reassess and intensify therapy.

Related ACR Topics and Tools

This article covers one specific variant within the broader topic of managing acute pulmonary embolism. For a comprehensive overview of all clinical scenarios and their respective ACR ratings, please consult our parent guide. For additional resources on imaging criteria, protocols, and radiation safety, the following GigHz tools are available.

Frequently Asked Questions

Does the location of the bilateral emboli (central vs. peripheral) change this recommendation?

In this specific low-risk scenario, as long as the patient is hemodynamically stable with no evidence of right heart strain (RV/LV ratio < 0.9, normal troponin), the initial therapy remains anticoagulation alone, regardless of whether the emboli are central or peripheral. The physiological impact, not the anatomical location, drives the initial therapeutic decision.

Why is an RV/LV ratio of 0.9 the cutoff?

The RV/LV ratio is a validated prognostic marker in acute PE. A ratio of 0.9 or greater on CTA is strongly associated with right ventricular dysfunction and an increased risk of adverse outcomes. While any cutoff is a simplification, 0.9 is a widely used threshold to distinguish between low-risk PE and submassive PE, which may warrant more aggressive management.

If the patient is stable, can they be treated as an outpatient?

Yes, select low-risk PE patients can be considered for outpatient therapy. This decision depends on validated risk scores (like PESI or Hestia criteria) and an assessment of the patient’s social support, ability to obtain medication, and access to follow-up. The key is to ensure the patient is truly low-risk and has a safe discharge plan.

Is a follow-up CT scan needed to confirm the clot has resolved?

Routine follow-up imaging is generally not recommended for patients who have clinically recovered from an acute PE. The decision to anticoagulate and the duration of therapy are based on the initial diagnosis and clinical factors, not on the radiographic resolution of the clot, which can lag behind clinical improvement.

What if the troponin is normal but the RV/LV ratio is 1.0?

If the RV/LV ratio is 1.0, the patient no longer fits this low-risk scenario, even with a normal troponin. They would be classified as having a submassive PE due to the evidence of right ventricular dilation on CTA. This finding necessitates a different clinical workflow, often involving a multidisciplinary discussion about the potential role of more advanced therapies like catheter-directed thrombolysis.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026